Quotables
"We are probably nearing the limit of all we can know about astronomy."
Simon Newcomb, astronomer ; 1888
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8124093 | Human cytomegalovirus neutralizing antibodies and use thereof The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention als... | 02/28/2012 |
| 8124091 | Human monoclonal antibodies to influenza M2 protein and methods of making and using same Human, humanized and chimeric monoclonal antibodies that bind to influenza M2 protein. A human monoclonal antibody that binds to influenza M2 protein having different amino acid sequences. The antibodies are useful for, among other things, treatment, diagnostics, pu... | 02/28/2012 |
| 8124092 | Antibodies against H5N1 strains of influenza A virus Provided are human antibodies that can neutralize a H5N1 strain of influenza A virus. Also provided are antibodies that can neutralize a strain of influenza A virus in clade 2 of the H5 subtype, that can neutralize a H5N1 strain of influenza A virus and have a lambd... | 02/28/2012 |
| 8114402 | Compositions and methods for the therapy and diagnosis of influenza The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection. ... | 02/14/2012 |
| 8057796 | Compositions and methods for the therapy and diagnosis of influenza The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection. ... | 11/15/2011 |
| 8052974 | Host cell specific binding molecules capable of neutralizing viruses and uses thereof The present invention provides human binding molecules specifically binding to a host cell protein and having virus neutralizing activity, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of... | 11/08/2011 |
| 7988971 | Human monoclonal antibodies against Hendra and Nipah viruses The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nip... | 08/02/2011 |
| 7988972 | Immunoreactive peptides from Epstein-Barr virus The Epstein-Barr virus (EBV) specific polypeptides ETFTETWNRFITHTE (SEQ. ID NO: 1), GMLEASEGLDGWIHQ (SEQ. ID NO:2), HQQGGWSTLIEDNIP (SEQ. ID NO:3), and KQKHPKKVKQAFNPL (SEQ. ID NO:4) are among those disclosed. Also disclosed are the use of these polypeptides for the... | 08/02/2011 |
| 7981422 | Antibodies against West Nile Virus and therapeutic and prophylactic uses thereof The present invention relates to compositions comprising antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV), and methods for preventing, treating or ameliorating symptoms associ... | 07/19/2011 |
| 7959922 | Liquid anti-rabies antibody formulations The present invention provides pharmaceutical antibody formulations, in particular liquid pharmaceutical formulations comprising anti-rabies virus antibodies. The formulations can be used in the post exposure prophylaxis of rabies. ... | 06/14/2011 |
| 7955599 | Human cytomegalovirus neutralizing antibodies and use thereof The invention relates to neutralising antibodies which are specific for human cytomegalovirus and bind with high affinity as well as immortalised B cells that produce such antibodies. The invention also relates to the epitopes that the antibodies bind to as well as ... | 06/07/2011 |
| 7947274 | Human cytomegalovirus neutralising antibodies and use thereof The invention relates to neutralizing antibodies and antibody fragments having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for a combination of hCMV proteins UL130 and UL131A, or for a combination of hCMV proteins U... | 05/24/2011 |
| 7867497 | Monoclonal antibodies to respiratory syncytial virus and uses therefor The present invention is directed to particular human monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of respiratory syncytial virus infections. In particular, these antibodies may neutralize RSV. Also disclosed a... | 01/11/2011 |
| 7837996 | Materials and methods for treatment of hepatitis C The present invention relates to materials and methods for treatment of hepatitis C. More closely, the invention relates to human monoclonal antibodies against HCV E1 antigen, to a reagent comprising such antibodies, and to vaccine compositions comprising such antib... | 11/23/2010 |
| 7811568 | Smallpox monoclonal antibody Humanized monoclonal antibodies against the vaccinia virus B5R surface antigen. The antibodies are effective in treating smallpox infection. Also disclosed are nucleic acids that encode the heavy and light chains of such antibodies and cells that express them. ... | 10/12/2010 |
| 7740852 | Binding molecules capable of neutralizing rabies virus and uses thereof Provided are binding molecules that specifically bind to rabies virus and are capable of neutralizing the virus. Further provided are nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules and methods of identifying or p... | 06/22/2010 |
| 7740851 | Ultra high affinity neutralizing antibodies Ultra high affinity antibodies with binding affinities in the range of 1010 M−1, and even 1011 M−1 are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs)... | 06/22/2010 |
| 7736648 | Anti-RSV G protein antibodies Individual monoclonal antibodies and fragments that bind a conserved epitope of the G protein of RSV and which are minimally immunogenic when administered to a human subject, are useful in treating RSV infections. ... | 06/15/2010 |
| 7704505 | Human-murine chimeric antibodies against respiratory syncytial virus This invention relates to a human antibody which contains the one CDR from each variable heavy and variable light chain of at least one murine monoclonal antibody, against respiratory syncytial virus which is MAb1129 and the use thereof for the prevention and/or tre... | 04/27/2010 |
| 7666420 | Composition for treating pathology associated with MSRV/HERV-W The inventive composition comprises at least one type of antibody selected in a group (i) of anti-Env-SU MSRV/HERV-W antibodies or in a group of anti-TLR4 antibodies specifically linkable with the soluble fraction of an Env protein of MSRV/HERV-W or to a TLR4 recept... | 02/23/2010 |
| 7488477 | Neutralizing monoclonal antibodies to respiratory syncytial virus The present invention relates to the identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratory Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibod... | 02/10/2009 |
| 7482006 | Recombinant enterovirus 71 neutralizing antibodies and applications thereof Provided is an antibody against enterovirus 71 comprising the amino acid sequence shown in SEQ ID NOS: 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26 or functionally active homologues thereof. Also provided are methods for obtaining the antibody comprising (a... | 01/27/2009 |
| 7429381 | Production and use of novel peptide-based agents for use with bi-specific antibodies The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a linker moiety. The linker moiety encompasses a hapten to which antib... | 09/30/2008 |
| 7393533 | H3L envelope protein immunization methods and H3L envelope passive protection methods The invention relates to, among other things, methods of protecting against poxvirus infection or pathogenesis and including pox viruses such as small pox (variola major and variola minor), cowpox, monkey pox vaccinia virus, and Molluscum Contagiosum using compositi... | 07/01/2008 |
| 7364737 | Human neutralizing monoclonal antibodies to respiratory syncytial virus Human monoclonal antibodies and fragments thereof which bind, neutralize and provide passive immunotherapy to respiratory syncytial virus (RSV) antigenic subgroups A and B are disclosed. Also disclosed are diagnostic and immunotherapeutic methods of using the monocl... | 04/29/2008 |
| 7354584 | Recombinant IL-9 antibodies The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases... | 04/08/2008 |
| 7306807 | Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease The present invention relates to a novel, isolated and purified hemorrhagic feline calicivirus FCV-DD1. The invention further embraces monovalent and multivalent vaccines containing the new FCV-DD1 strain. In addition, the invention encompasses methods of protecting... | 12/11/2007 |
| 7306798 | Immunoglobulin IgG3 as a marker for protecting against infectious viral diseases, and the uses of the same The invention relates to a novel variant of isolated and/or purified immunoglobulin IgG3 which can be used as a marker for protecting against infectious viral diseases such as AIDS, as a diagnostic tool, or as a preventive and curative medicament. The invention also... | 12/11/2007 |
| 7294336 | Stabilized liquid anti-RSV antibody formulations The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and v... | 11/13/2007 |
| 7282341 | Assay for the diagnosis of flaviviral infection using antibodies with high affinity for NS1 protein of flavivirus in hexameric form The invention concerns a method for early detection of a flavivirus-induced infection, comprising the detection of the flavivirus non-structural glycoprotein NS1 in a biological sample during the clinical phase of the infection, by an immumological method using at l... | 10/16/2007 |
| 7276334 | Construction and characterization of monoclonal antibodies against western equine encephalitis virus Construction and characterization of mouse monoclonal antibodies against western equine encephalitis virus (WEE) for potential use in detection, diagnosis, and immunotherapy are disclosed. Antibodies were prepared from hybridoma cells and further characterized by EL... | 10/02/2007 |
| 7229619 | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory sy... | 06/12/2007 |
| 7208162 | Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents Therapeutically effective anti-viral compositions, useful especially against respiratory diseases caused or mediated by respiratory syncytial virus (RSV) are disclosed, wherein said compositions comprise at least one anti-RSV antibody, including high affinity antibo... | 04/24/2007 |
| 7163798 | Method of preparing cow brain homogenate An assay method is disclosed which isolates and detects the presence of a disease related conformation of a protein (e.g., PrPSc) present in a sample also containing the non-disease related conformation of the protein (e.g., PrPC). The sample i... | 01/16/2007 |
| 7132100 | Stabilized liquid anti-RSV antibody formulations The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and v... | 11/07/2006 |
| 7105303 | Antibodies to hepatitis C virus asialoglycoproteins Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more simi... | 09/12/2006 |
| 7087213 | Method of preparing cow brain homogenate A method of isolating and detecting the presence of a disease related conformation of a protein (e.g., PrPSc) is disclosed. The sample is treated such as by contacting it with a protease and then contacting the treated sample with a binding partner which ... | 08/08/2006 |
| 7067128 | Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype Polyspecific immunoconjugates and antibody composites that bind a multidrug transporter protein and an antigen associated with a tumor or infectious agent are used to overcome the multidrug resistant phenotype. These immunoconjugates and composites also can be used ... | 06/27/2006 |
| 7052675 | Antibodies specific for native PrP Antibodies are disclosed which specifically bind to native PrPSc in situ. Preferred antibodies bind only to the native PrPSc of a particular species e.g., human, cow, sheep, pig, etc. Particularly preferred antibodies bind specifically to a par... | 05/30/2006 |
| 7041813 | Canine herpes virus alpha transinducing factor nucleic acid molecules The present invention includes novel recombinant canine herpes virus (CHV) and novel recombinant CHV genomes, and particularly to those CHV and CHV genomes that contain heterologous nucleic acid molecules. The present invention also relates to the use of such genome... | 05/09/2006 |
